ARTICLE | Company News

NeuroSearch neurology news

October 20, 2014 7:00 AM UTC

NeuroSearch appealed to the Eastern High Court of Denmark an August ruling from the City Court of Copenhagen ordering the company to pay a fine of DKK5 million ($851,000) for share price manipulation in violation of the Danish Securities Trading Act.

The 2013 case relates to an announcement issued on Feb. 3, 2010, in which the company reported top-line data from a Phase III trial to treat Huntington's disease showing Huntexil pridopidine met the primary endpoint of improving voluntary motor function. The data were subsequently reassessed and on April 28, 2010, NeuroSearch said the revised analysis showed that Huntexil did not meet the primary endpoint in the trial (see BioCentury, July 29, 2013). ...